155 related articles for article (PubMed ID: 37633201)
1. Efficacy of induction chemotherapy in lymph node-positive stage III nasopharyngeal carcinoma and identification of beneficiaries based on clinical features: A propensity score matching analysis.
Xu YC; Chen KH; Liang Y; Chen KQ; Liang ZG; Zeng FY; Li L; Qu S; Zhu XD
Oral Oncol; 2023 Nov; 146():106554. PubMed ID: 37633201
[TBL] [Abstract][Full Text] [Related]
2. Comparison of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in Lymph-Node-Stage III nasopharyngeal carcinoma based on propensity score-matching.
Liu ZC; Zeng KH; Gu ZB; Chen RP; Luo YJ; Tang LQ; Zhu KB; Liu Y; Sun XS; Zeng L
Radiother Oncol; 2023 Jan; 178():109421. PubMed ID: 36410548
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of adjuvant chemotherapy/maintenance chemotherapy after induction chemotherapy and concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Experiences of two centers.
Tao HY; He F; Shi QY; Liu R; Wang ZL; Du KP; Li JF; Liu H; Lu ZQ; Zhang JJ; Bai YH
Cancer Med; 2023 Mar; 12(6):6811-6824. PubMed ID: 36420689
[TBL] [Abstract][Full Text] [Related]
4. Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
Mu X; Liu H; Wu J; Chen S; Peng X; Wang J; Wei Z; He L; Liu J; Lu Z; Su Y
Aging (Albany NY); 2022 Aug; 14(16):6727-6739. PubMed ID: 36036759
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of induction chemotherapy or adjuvant chemotherapy added to concurrent chemoradiotherapy in T3-4N0-1M0 nasopharyngeal carcinoma: a propensity score-matched analysis.
Zhong Q; Luo D; Li X; Du Q; Liang Q; Liu W; Li J; Zhu X
Cancer Biol Ther; 2023 Dec; 24(1):2274121. PubMed ID: 37965924
[TBL] [Abstract][Full Text] [Related]
6. MRI-based radiomics to compare the survival benefit of induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A multicenter study.
Shen H; Yin J; Niu R; Lian Y; Huang Y; Tu C; Liu D; Wang X; Lan X; Yuan X; Zhang J
Radiother Oncol; 2022 Jun; 171():107-113. PubMed ID: 35461950
[TBL] [Abstract][Full Text] [Related]
7. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study.
Guo SS; Tang LQ; Chen QY; Zhang L; Liu LT; Guo L; Mo HY; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Wang L; Lv X; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
Oncotarget; 2016 May; 7(20):29739-48. PubMed ID: 27105538
[TBL] [Abstract][Full Text] [Related]
8. Induction Chemotherapy Plus Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma in Children and Adolescents: A Matched Cohort Analysis.
Li Y; Tang LQ; Liu LT; Guo SS; Liang YJ; Sun XS; Tang QN; Bei JX; Tan J; Chen S; Ma J; Zhao C; Chen QY; Mai HQ
Cancer Res Treat; 2018 Oct; 50(4):1304-1315. PubMed ID: 29334605
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of adding PD-1 blockade to induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) for locoregionally advanced nasopharyngeal carcinoma: an observational, propensity score-matched analysis.
Jin YN; Qiang MY; Wang Y; Lin YJ; Jiang RW; Cao WW; Zhang WJ; Wang SY; Zhang HY; Yao JJ
Cancer Immunol Immunother; 2024 May; 73(7):125. PubMed ID: 38733402
[TBL] [Abstract][Full Text] [Related]
10. Concurrent chemoradiotherapy combined with nimotuzumab in stage III-IVa nasopharyngeal carcinoma: a retrospective analysis.
Cai Z; Chen D; Qiu W; Liang C; Huang Y; Zhou J; Zhan Z; Xiang Y; Guo X; Lv X
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2327-2344. PubMed ID: 36289067
[TBL] [Abstract][Full Text] [Related]
11. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
Wei Z; Zhang Z; Luo J; Li N; Peng X
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
[TBL] [Abstract][Full Text] [Related]
12. Induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus volumetric modulated arc therapy alone in the treatment of stage II-IVB nasopharyngeal carcinoma patients: a retrospective controlled study.
Liu L; Fei Z; Chen M; Zhao L; Su H; Gu D; Lin B; Cai X; Lu L; Gao M; Ye X; Jin X; Xie C
Radiat Oncol; 2018 Aug; 13(1):148. PubMed ID: 30103765
[TBL] [Abstract][Full Text] [Related]
13. The impairment of induction chemotherapy for stage II nasopharyngeal carcinoma treated with intensity-modulated radiotherapy with or without concurrent chemotherapy: A propensity score-matched analysis.
Lai Y; Wang C; Yang X; He S; Wang Y; Chen Y
Cancer Med; 2023 Feb; 12(3):2970-2978. PubMed ID: 36114787
[TBL] [Abstract][Full Text] [Related]
14. Individualized cumulative cisplatin dose for locoregionally-advanced nasopharyngeal carcinoma patients receiving induction chemotherapy and concurrent chemoradiotherapy.
Wen DW; Li ZX; Chen FP; Lin L; Peng BY; Kou J; Zheng WH; Yang XL; Xu SS; Sun Y; Zhou GQ
Oral Oncol; 2020 Aug; 107():104675. PubMed ID: 32361563
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era.
Li PJ; Mo HY; Luo DH; Hu WH; Jin T
Oral Oncol; 2018 Oct; 85():95-100. PubMed ID: 30220326
[TBL] [Abstract][Full Text] [Related]
16. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial.
Yang Q; Cao SM; Guo L; Hua YJ; Huang PY; Zhang XL; Lin M; You R; Zou X; Liu YP; Xie YL; Wang ZQ; Mai HQ; Chen QY; Tang LQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Li JB; Ling L; Guo X; Hong MH; Chen MY
Eur J Cancer; 2019 Sep; 119():87-96. PubMed ID: 31425966
[TBL] [Abstract][Full Text] [Related]
17. Concurrent chemoradiotherapy versus radiotherapy alone in older patients with stage II nasopharyngeal carcinoma after intensity-modulated radiotherapy: A propensity score-matched cohort study.
Wang F; Zhou L; Zhang LJ; Xie CB; Liao ZW; Lin XD; Wen YF
Radiother Oncol; 2024 Feb; 191():110081. PubMed ID: 38185256
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant chemotherapy following combined induction chemotherapy and concurrent chemoradiotherapy improves survival in N2-3-positive nasopharyngeal carcinoma patients.
Tao HY; Liu H; He F; He CX; Li R; Du KP; Yuan YW; Zheng RH
J Cancer Res Clin Oncol; 2022 Nov; 148(11):2959-2969. PubMed ID: 34822015
[TBL] [Abstract][Full Text] [Related]
19. Can Epstein-Barr virus-deoxyribonucleic acid load after induction chemotherapy combined with American Joint Committee on Cancer stage determine the chemotherapy intensity of locally advanced nasopharyngeal carcinoma?
Zhang Q; Peng ZW; Gu ZS; Wang Y; He F; Zhao WB; Luo W; Mei YY
Cancer Med; 2023 Jan; 12(1):223-235. PubMed ID: 35674137
[TBL] [Abstract][Full Text] [Related]
20. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
Xu C; Sun R; Tang LL; Chen L; Li WF; Mao YP; Zhou GQ; Guo R; Lin AH; Sun Y; Ma J; Hu WH
Oral Oncol; 2018 Mar; 78():37-45. PubMed ID: 29496056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]